Nine new crown vaccine manufacturers have made a joint commitment to ensure vaccine safety.

According tomedia reports, a vaccine may end the new crown pandemic, but it will take a long time to achieve. First, the world needs at least one safe and effective vaccine to successfully complete the final phase of trials, then people need to wait for governments to develop and implement vaccination campaigns, and people need to continue to observe safety measures designed to reduce the spread of the disease — wearing masks, keeping social distances, washing their hands regularly.

Nine new crown vaccine manufacturers have made a joint commitment to ensure vaccine safety.

That’s because it will take some time for a large part of the world’s population to be vaccinated. Even so, the virus will not be eradicated. And to do that, we need a very effective vaccine and make sure everyone is vaccinated.

But as the end of the year approaches, there are growing concerns about the safety of vaccines. More and more Americans are questioning the effectiveness and safety of experimental drugs. A recent poll showed that two-thirds of Americans said they would not get vaccinated immediately once the new vaccine was on the market, while a third said they would never get vaccinated. This has prompted some pharmaceutical giants to sign up to a new crown virus vaccine research commitment to ensure that the public can only be approved for use if their safety is guaranteed.

Recent reports that the Trump administration may want to urgently approve a Phase III drug ahead of the November 3 presidential election understand why more and more people are wary of the current new vaccine.

Now, nine companies have announced that they have signed a commitment to “stand with science.” Pfizer and its new crown vaccine partners BioNTech, AstraZeneta, GlaxoSmithKline, Johnson and Johnson, Moderna, Novavax and Sanofi have all signed up to the historic commitment.

For those who are hesitant about vaccines, the words on virtual paper may not make much sense, but they are still a significant effort by these fierce competitors. In a year when conspiracy theories and unproven therapies have hampered the work of new crown control and treatment, it is necessary to recognize the importance of science. This may reassure some that the ongoing Hi-Hay vaccine program will put science first, not political or economic interests.

Pfizer/BioNTech, AstraZenecon/Oxford and Moderna are likely to report the findings of their Phase 3 clinical trials in the coming months. Other signatories to this commitment will also receive more vaccine data in the near future. If these drugs prove to be effective and safe, you may soon know what to expect from the new crown vaccination campaign.